An interventional study of Hemi-tibial plateau osteotomy combined with arthroscopic repair and High tibial osteotomy combined with arthroscopic repair in Knee Osteoarthristis and Meniscus Injury, sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Eighth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center clinical trial started by the study team. The goal is to compare two surgeries for people who have a varus knee alignment and a tear at the back attachment of the medial meniscus. Researchers want to learn how the newer bone-cut procedure with arthroscopic meniscus repair compares to the standard bone-cut procedure with arthroscopic meniscus repair. Researchers will also track safety and hospital-related costs.
Main questions the study aims to answer:
Study groups:
Who may join:
Who cannot join:
What participants will do:
Outcomes:
Eighth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 10 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Hemi-tibial plateau osteotomy combined with arthroscopic repair
Procedure: High tibial osteotomy combined with arthroscopic repair
The intervention is hemi-tibial plateau osteotomy combined with arthroscopic repair of the medial meniscus posterior root (HTPO combined with arthroscopic repair). After anesthesia and supine positioning, the medial compartment is opened by releasing the distal attachment of the superficial medial collateral ligament. Under fluoroscopic guidance, an L-shaped osteotomy is performed with the horizontal cut approximately 3.0 cm below the tibial plateau, while preserving the articular surface continuity at the hinge area to protect the cartilage and meniscus. A controlled valgus force is then applied to gradually open the osteotomy gap, and the lower-limb alignment is corrected to the preplanned target and confirmed by fluoroscopy. Arthroscopic repair of the medial meniscus posterior root is subsequently performed. The distal attachment of the superficial medial collateral ligament is advanced proximally and fixed below the horizontal osteotomy line, and the osteotomy is stabilized with a
The control intervention is high tibial osteotomy combined with arthroscopic repair of the medial meniscus posterior root (HTO combined with arthroscopic repair). After anesthesia and supine positioning, the high tibial osteotomy is performed under fluoroscopic guidance according to the preoperative plan. A controlled valgus force is gradually applied to open the osteotomy gap, and the lower-limb alignment is corrected to the preplanned target and confirmed by fluoroscopy. Arthroscopic evaluation is then performed, followed by arthroscopic repair of the medial meniscus posterior root. The osteotomy site is stabilized with a proximal medial tibial anatomic locking titanium plate, and final fluoroscopic confirmation of alignment and fixation stability is obtained before wound closure.
Change From Baseline in Lysholm Knee Score (12 months)
Lysholm knee score will be assessed preoperatively (baseline) and at 12 months after surgery. The primary endpoint is the change from baseline to 12 months (12-month score minus baseline score). Higher scores indicate better knee function.
Time frame: Baseline (preoperative) and 12 months after surgery
Change From Baseline in Lysholm Knee Score (3 and 6 Months)
Lysholm knee score will be assessed at baseline (preoperative) and at 3 and 6 months after surgery. The outcome is change from baseline at each time point (score at follow-up minus baseline score). Higher scores indicate better knee function.
Time frame: Baseline (preoperative), 3 months, and 6 months after surgery
Change From Baseline in WOMAC Total Score (3, 6, and 12 Months)
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score will be assessed at baseline and at 3, 6, and 12 months after surgery. The outcome is change from baseline at each time point (follow-up minus baseline). WOMAC total score ranges from 0 to 96, with lower scores indicating better symptoms/function.
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Change From Baseline in Pain Score (VAS) (3, 6, and 12 Months)
Pain will be assessed using a 10-cm visual analogue scale (VAS) at baseline and at 3, 6, and 12 months after surgery. The outcome is change from baseline at each time point (follow-up minus baseline). The VAS ranges from 0 (no pain) to 10 (worst pain).
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Change in Mechanical Axis Location on Tibial Plateau (%MA) on Full-Length Lower Limb Radiographs
On bilateral standing full-length lower limb radiographs, the mechanical axis (MA) will be evaluated by the relative location where the mechanical axis crosses the tibial plateau, expressed as a percentage (%MA). The outcome is %MA at each time point and change from baseline.
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Change in EQ-5D-5L Health Utility Value
Health-related quality of life will be assessed using the EQ-5D-5L questionnaire and converted to a health utility value using the China EQ-5D-5L value set. The outcome is the utility value at each time point and change from baseline (follow-up minus baseline).
Time frame: Baseline (screening/preoperative), 0-7 days after surgery, 3 months, 6 months, and 12 months after surgery
Quality-Adjusted Life Years (QALYs) Over 12 Months
QALYs will be calculated over the 12-month follow-up period using EQ-5D-5L utility values collected at scheduled visits (area-under-the-curve approach). The outcome is total QALYs accrued from baseline to 12 months.
Time frame: Baseline to 12 months after surgery
Change in Kellgren-Lawrence Grade on Knee Radiographs
Kellgren-Lawrence (K-L) grade will be assessed on knee radiographs at each time point to evaluate radiographic severity of knee osteoarthritis (grades 0-IV). The outcome is K-L grade at each time point.
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Bone Healing Grade at the Osteotomy Site (Modified Van Hemert System)
Bone healing at the osteotomy site will be graded using a modified Van Hemert system on radiographs. Grades range from 1 to 5, where higher grades indicate more bridging callus and better healing (grade 5 indicates complete bridging). The outcome is healing grade at each time point.
Time frame: 0-7 days after surgery, 3 months, 6 months, and 12 months after surgery
Medial Meniscus Healing Status on MRI
Medial meniscus posterior root healing will be assessed on MRI and categorized as complete healing, partial healing, or non-healing. Complete healing is defined as continuity of the repaired root seen on all three MRI planes (sagittal, coronal, and axial). Partial healing indicates loss of continuity in any one plane, and non-healing indicates no continuity in any plane. The outcome includes healing category and the proportion of participants in each category at each time point.
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Change in Medial Meniscus Extrusion Distance on MRI
Medial meniscus extrusion will be measured on MRI as the distance between the outer edge of the medial meniscus and the edge of the medial tibial plateau on a standardized reference line. Outcomes include extrusion distance at each time point and change from baseline.
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Surgery-Related Outcomes, Complications, and Hospital Resource Use
Surgery-related outcomes will include operative time and intraoperative blood loss. Safety outcomes will include intraoperative and postoperative complications (e.g., common peroneal nerve injury, deep vein thrombosis, infection, implant failure, delayed union, or nonunion). Hospital resource use will include length of hospital stay and hospitalization costs. Outcomes will be recorded during the perioperative period and through 12 months after surgery.
Time frame: 0-7 days after surgery; 3 months, 6 months, and 12 months after surgery (complications assessed through 12 months)
Change in Joint Line Convergence Angle (JLCA) on Standing Knee Radiographs
JLCA will be measured on standing anteroposterior knee radiographs. The outcome is JLCA (degrees) at each time point and change from baseline (follow-up minus baseline).
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Change in Medial Joint Space Width (JS) on Standing Knee Radiographs
Medial joint space width will be measured on standing anteroposterior knee radiographs. The outcome is joint space width (e.g., mm) at each time point and change from baseline (follow-up minus baseline).
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Change in Posterior Proximal Tibial Angle (PPTA) on Knee Radiographs
PPTA will be measured on knee radiographs. The outcome is PPTA (degrees) at each time point and change from baseline (follow-up minus baseline).
Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery
Change in Posterior Tibial Slope (PTS) on Lateral Knee Radiographs
Posterior tibial slope will be measured on lateral knee radiographs. The outcome is PTS (degrees) at each time point and change from baseline (follow-up minus baseline).
Time frame: Posterior tibial slope will be measured on lateral knee radiographs. The outcome is PTS (degrees) at each time point and change from baseline (follow-up minus baseline).
Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eighth Affiliated Hospital, Sun Yat-sen University